Inhibrx Biosciences/$INBX
1D1W1MYTD1Y5YMAX
Capital at risk
About Inhibrx Biosciences
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
- Ticker
- $INBX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 110
- Headquarters
- La Jolla, United States
- Website
- inhibrx.com
INBX Metrics
BasicAdvanced
$1.6B
-
-$8.88
3.52
-
Price and volume
Market cap
$1.6B
Beta
3.52
52-week high
$155.29
52-week low
$26.19
Average daily volume
325K
Financial strength
Current ratio
5.067
Quick ratio
4.756
Long term debt to equity
-3.381
Total debt to equity
-3.428
Interest coverage (TTM)
-8.21%
Profitability
EBITDA (TTM)
-125.604
Effective tax rate (TTM)
-0.00%
Management effectiveness
Return on assets (TTM)
-43.61%
Return on equity (TTM)
-1,773.60%
Valuation
Price to book
-30.67
Price to tangible book (TTM)
-30.67
Price to free cash flow (TTM)
-13.037
Free cash flow yield (TTM)
-7.67%
Free cash flow per share (TTM)
-8.473
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
-16.12%
3-year earnings per share growth (CAGR)
17.56%
What the Analysts think about INBX
Analyst ratings (Buy, Hold, Sell) for Inhibrx Biosciences stock.
Analyst projections of the future price of Inhibrx Biosciences stock.
Bulls say / Bears say
In May 2026, Inhibrx reported positive interim Phase 2 HexAgon study results for INBRX-106 in first-line HNSCC, demonstrating a confirmed objective response rate of 44.0% versus 21.4% with pembrolizumab alone and robust T-cell activation, supporting initiation of a Phase 3 registrational trial in 3Q 2026. (SEC filing)
On June 15, 2026, the FDA accepted for filing Inhibrx’s Biologics License Application for ozekibart (INBRX-109) in conventional chondrosarcoma and set a PDUFA goal date of April 14, 2027, marking a key regulatory milestone. (SEC filing)
In July 2026, Inhibrx entered into a second amendment to its Oxford Finance loan facility, expanding the credit agreement by $325 million (including $100 million funded) to a total capacity of $500 million, strengthening its liquidity profile. (SEC filing)
In Q2 2026, Inhibrx’s net loss widened to $36.7 million, or $2.34 per share, compared to a net loss of $28.7 million, or $1.85 per share, in Q2 2025, due to higher R&D and G&A expenses. (SEC filing)
The company reported zero revenue in Q2 2026 versus $1.3 million in Q2 2025, underscoring the absence of any product sales or collaboration income. (SEC filing)
Long-term debt rose to $176.3 million as of June 30, 2026 from $100.6 million at December 31, 2025, increasing interest expense and financial leverage. (SEC filing)
Data summarised monthly by Lightyear AI. Last updated on 29 Aug 2026.
INBX Financial Performance
Revenues and expenses
INBX Earnings Performance
Company profitability
Upcoming events
No upcoming events
INBX News
AllArticlesVideos
Funds containing INBX
AllUSDGBPEUR
Fund name | Fund size | $INBX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.08% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.08% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.04% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.